Universe Pharmaceuticals Net Income
| UPC Stock | USD 2.95 0.04 1.34% |
As of the 25th of February, Universe Pharmaceuticals has the Variance of 56.84, coefficient of variation of (48,865), and Risk Adjusted Performance of 0.0074. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Universe Pharmaceuticals, as well as the relationship between them.
Universe Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 0.0174 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -3.3 M | -3.1 M | |
| Net Loss | -7.9 M | -7.5 M | |
| Net Loss | -3.3 M | -3.1 M | |
| Net Loss | -1.2 K | -1.2 K | |
| Net Income Per E B T | 0.97 | 0.78 |
Universe | Net Income | Build AI portfolio with Universe Stock |
Analyzing Universe Pharmaceuticals's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Universe Pharmaceuticals's current valuation and future prospects.
Latest Universe Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Universe Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Universe Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Universe Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Universe Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Universe Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (3.67 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Universe Net Income Regression Statistics
| Arithmetic Mean | 3,147,627 | |
| Geometric Mean | 6,761,835 | |
| Coefficient Of Variation | 219.11 | |
| Mean Deviation | 6,191,671 | |
| Median | 7,602,933 | |
| Standard Deviation | 6,896,741 | |
| Sample Variance | 47.6T | |
| Range | 20.1M | |
| R-Value | (0.73) | |
| Mean Square Error | 23.5T | |
| R-Squared | 0.54 | |
| Significance | 0.0008 | |
| Slope | (1,000,708) | |
| Total Sum of Squares | 761T |
Universe Net Income History
Other Fundumenentals of Universe Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Universe Pharmaceuticals Net Income component correlations
Universe Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Universe Pharmaceuticals is extremely important. It helps to project a fair market value of Universe Stock properly, considering its historical fundamentals such as Net Income. Since Universe Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Universe Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Universe Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Universe diversify its offerings? Factors like these will boost the valuation of Universe Pharmaceuticals. If investors know Universe will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Universe Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.82) | Earnings Share (8.06) | Revenue Per Share | Quarterly Revenue Growth (0.14) | Return On Assets |
The market value of Universe Pharmaceuticals is measured differently than its book value, which is the value of Universe that is recorded on the company's balance sheet. Investors also form their own opinion of Universe Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Universe Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Universe Pharmaceuticals' market value can be influenced by many factors that don't directly affect Universe Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Universe Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Universe Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Universe Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Universe Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Universe Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Universe Pharmaceuticals.
| 11/27/2025 |
| 02/25/2026 |
If you would invest 0.00 in Universe Pharmaceuticals on November 27, 2025 and sell it all today you would earn a total of 0.00 from holding Universe Pharmaceuticals or generate 0.0% return on investment in Universe Pharmaceuticals over 90 days. Universe Pharmaceuticals is related to or competes with Painreform, Elevai Labs, Bluejay Diagnostics, Tivic Health, Moolec Science, BriaCell Therapeutics, and Shuttle Pharmaceuticals. Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of... More
Universe Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Universe Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Universe Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 52.35 | |||
| Value At Risk | (9.34) | |||
| Potential Upside | 13.75 |
Universe Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Universe Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Universe Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Universe Pharmaceuticals historical prices to predict the future Universe Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0074 | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (0.99) | |||
| Treynor Ratio | (0.02) |
Universe Pharmaceuticals February 25, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0074 | |||
| Market Risk Adjusted Performance | (0.01) | |||
| Mean Deviation | 4.93 | |||
| Coefficient Of Variation | (48,865) | |||
| Standard Deviation | 7.54 | |||
| Variance | 56.84 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (0.99) | |||
| Treynor Ratio | (0.02) | |||
| Maximum Drawdown | 52.35 | |||
| Value At Risk | (9.34) | |||
| Potential Upside | 13.75 | |||
| Skewness | 0.8522 | |||
| Kurtosis | 4.76 |
Universe Pharmaceuticals Backtested Returns
Universe Pharmaceuticals owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0245, which indicates the firm had a -0.0245 % return per unit of risk over the last 3 months. Universe Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Universe Pharmaceuticals' Variance of 56.84, coefficient of variation of (48,865), and Risk Adjusted Performance of 0.0074 to confirm the risk estimate we provide. The entity has a beta of 1.44, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Universe Pharmaceuticals will likely underperform. At this point, Universe Pharmaceuticals has a negative expected return of -0.19%. Please make sure to validate Universe Pharmaceuticals' value at risk, as well as the relationship between the accumulation distribution and day typical price , to decide if Universe Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.27 |
Weak reverse predictability
Universe Pharmaceuticals has weak reverse predictability. Overlapping area represents the amount of predictability between Universe Pharmaceuticals time series from 27th of November 2025 to 11th of January 2026 and 11th of January 2026 to 25th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Universe Pharmaceuticals price movement. The serial correlation of -0.27 indicates that nearly 27.0% of current Universe Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.27 | |
| Spearman Rank Test | -0.14 | |
| Residual Average | 0.0 | |
| Price Variance | 0.38 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Universe Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Universe Pharmaceuticals reported net income of (3.67 Million). This is 101.08% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 100.64% higher than that of the company.
Universe Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Universe Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Universe Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Universe Pharmaceuticals by comparing valuation metrics of similar companies.Universe Pharmaceuticals is currently under evaluation in net income category among its peers.
Universe Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Universe Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Universe Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Universe Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Universe Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Universe Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Universe Pharmaceuticals' value.| Shares | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 0.0 | Sabby Management Llc | 2025-03-31 | 0.0 | Anson Funds Management Lp | 2025-03-31 | 0.0 | Ubs Group Ag | 2025-06-30 | 0.0 |
Universe Fundamentals
| Return On Equity | -0.0723 | ||||
| Return On Asset | -0.0266 | ||||
| Profit Margin | (0.21) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | (37.01 M) | ||||
| Shares Outstanding | 563.34 K | ||||
| Shares Owned By Insiders | 0.61 % | ||||
| Shares Owned By Institutions | 5.10 % | ||||
| Number Of Shares Shorted | 11.68 K | ||||
| Price To Earning | 3.02 X | ||||
| Price To Book | 0.05 X | ||||
| Price To Sales | 0.09 X | ||||
| Revenue | 17.86 M | ||||
| Gross Profit | 6.3 M | ||||
| EBITDA | (2.92 M) | ||||
| Net Income | (3.67 M) | ||||
| Cash And Equivalents | 28.58 M | ||||
| Cash Per Share | 1.31 X | ||||
| Total Debt | 9.26 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 5.06 X | ||||
| Book Value Per Share | 99.64 X | ||||
| Cash Flow From Operations | (5.05 M) | ||||
| Short Ratio | 0.47 X | ||||
| Earnings Per Share | (8.06) X | ||||
| Number Of Employees | 216 | ||||
| Beta | 1.52 | ||||
| Market Capitalization | 1.68 M | ||||
| Total Asset | 69.3 M | ||||
| Retained Earnings | (13.84 M) | ||||
| Working Capital | 40.43 M | ||||
| Net Asset | 69.3 M |
About Universe Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Universe Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Universe Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Universe Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Universe Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Universe Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Universe Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Universe Pharmaceuticals Stock:Check out For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Will Biotechnology sector continue expanding? Could Universe diversify its offerings? Factors like these will boost the valuation of Universe Pharmaceuticals. If investors know Universe will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Universe Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.82) | Earnings Share (8.06) | Revenue Per Share | Quarterly Revenue Growth (0.14) | Return On Assets |
The market value of Universe Pharmaceuticals is measured differently than its book value, which is the value of Universe that is recorded on the company's balance sheet. Investors also form their own opinion of Universe Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Universe Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Universe Pharmaceuticals' market value can be influenced by many factors that don't directly affect Universe Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Universe Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Universe Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Universe Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.